NuVasive Receives Consensus Rating of “Buy” from Analysts (NASDAQ:NUVA)
Shares of NuVasive (NASDAQ:NUVA) have been given an average recommendation of “Buy” by the twelve ratings firms that are covering the stock, Stock Ratings Network reports. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $42.60.
Shares of NuVasive (NASDAQ:NUVA) traded down 0.20% on Friday, hitting $34.83. 16,397 shares of the company’s stock traded hands. NuVasive has a one year low of $23.17 and a one year high of $39.89. The stock has a 50-day moving average of $35.39 and a 200-day moving average of $35.36. The company’s market cap is $1.635 billion.
NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.03. The company had revenue of $190.70 million for the quarter, compared to the consensus estimate of $177.50 million. During the same quarter in the previous year, the company posted $0.20 earnings per share. The company’s revenue for the quarter was up 15.1% on a year-over-year basis. On average, analysts predict that NuVasive will post $1.12 earnings per share for the current fiscal year.
A number of research firms have recently commented on NUVA. Analysts at Jefferies Group reiterated a “buy” rating on shares of NuVasive in a research note on Wednesday, July 30th. They now have a $48.00 price target on the stock, up previously from $45.00. Separately, analysts at Barclays reiterated an “equal weight” rating on shares of NuVasive in a research note on Wednesday, July 30th. They now have a $42.00 price target on the stock, up previously from $40.00. Finally, analysts at Goldman Sachs upgraded shares of NuVasive from a “neutral” rating to a “buy” rating in a research note on Wednesday, June 25th.
NuVasive, Inc is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.